AVXL - Investigation Into Anavex Life Sciences Corp. (AVXL) Announced by Holzer & Holzer LLC
ATLANTA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) complied with federal securities laws. On January 2, 2024, Anavex announced topline results from the phase 2/3 clinical trial, EXCELLENCE, and disclosed that the study failed to meet a “co-primary endpoint, the Clinical Global Impression – Improvement scale (CGI-I).” Following this news, the price of the Company’s stock dropped.
If you purchased Anavex stock and suffered?a?loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com , call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/anavex/ to discuss your legal rights.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com ,?and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com